|

AZD3470 Clinical Trials

2 actively recruiting trials across 2 locations

Pipeline

Phase 1/2: 2

Top Sponsors

  • AstraZeneca2

Indications

  • Cancer2
  • Non-Hodgkin1
  • Advanced Solid Tumors That Are MTAP Deficient1
  • Hodgkin Lymphoma1
  • Lymphoma1

San Francisco, California1 trial

A Study of AZD3470, a PRMT5 Inhibitor, in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors

Research Site

Phase 1/2

Miami, Florida1 trial

AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.

Research Site

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.